Dr. Robert Pacifici
CHDI's Translational Research Efforts to Develop Therapeutics for Huntington's Disease
Robert Pacifici is the Chief Scientific Officer of CHDI Foundation, a private, not-for-profit research organization that works with an international network of scientists to discover drugs that slow the progression or delay the onset of Huntington's disease. Previously he was the Site Director and Chief Scientific Officer at the Research Triangle Park Laboratories of Eli Lilly and Company. There he oversaw the company's global screening and quantitative-biology efforts. Prior to joining Lilly, Dr. Pacifici was Vice President of Discovery Technologies at Xencor, a privately held biotechnology company that applied rational design principles to the development of protein therapeutics. At Amgen for nearly ten years, Pacifici held positions of increasing responsibilities including leadership for their automation, high throughput screening, and information technologies groups. He currently holds an adjunct appointment at the University of Southern California's Department of Molecular Pharmacology and Toxicology, is Chair of the Spinal Muscular Atrophy Project's Scientific Steering Committee, which is part of the National Institute on Neurological Disorders and Stroke (NINDS), and sits on several additional external boards and advisory committees. Dr. Pacifici received a B.S. in Biochemistry from the University of Massachusetts, Amherst, and a Ph.D. in Biochemistry from the University of Southern California.